SAT0182 Sirukumab Leads to Significant and Clinically Meaningful Improvements in Health-Related Quality of Life That Meet or Exceed Normative Values in Patients With Rheumatoid Arthritis Refractory to TNF Inhibitors in Post Hoc Analyses of a Phase 3 Trial
